chufangao/CTO huggingface dataset:
Clinical trial NCT02366195: Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma
Official title: A Phase 2, Multicenter, Open-label, Single-arm Trial to Evaluate the Correlation Between Objective Response Rate and Baseline Intratumoral CD8+ Cell Density in Subjects With Unresected Stage IIIB to IVM1c Melanoma Treated With Talimogene Laherparepvec
Acronym: TVEC-325
Sponsor: Amgen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 112.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-04-07
Primary completion date: 2017-06-26
Completion date: 2020-12-25
Baseline population: Participants who received at least 1 dose of talimogene laherparepvec.
Plan to share individual participant data: YES
IPD sharing description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
IPD time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Clinical trial NCT01536717: Comparison of the Local Anaesthetics Articaine and Bupivacaine in Treatment of Acute Sternum Pain After Heart Surgery
Official title: Comparison of Periosteal and Subcutaneous Infusions of Articaine and Bupivacaine in Treatment of Acute Pain After Sternotomy
Sponsor: Helsinki University Central Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: SUSPENDED 
Enrollment: 36.0 (ACTUAL)
Number of arms: 2.0
Start date: 2012-03-31
Primary completion date: 2022-12-31
Completion date: 2022-12-31
Clinical trial NCT01908426: Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Official title: A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Acronym: CELESTIAL
Sponsor: Exelixis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 707.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-09-26
Primary completion date: 2017-10-16
Completion date: 2021-01-12
Clinical trial NCT04232397: Anlotinib Treatment in Steroid Depenent/Refractory cGVHD
Official title: A Phase 2 Study of Anlotinib in Subjects With Steroid Depenent/Refractory Chronic Graft Versus Host Disease(cGVHD)
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: the efficency is not good enough to enroll more patients
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-04-10
Primary completion date: 2020-09-15
Completion date: 2021-03-01
Clinical trial NCT02028806: mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer
Official title: Phase Ⅱ Trial to Investigate the Efficacy and Safety of mFOLFIRINOX in Patients With Metastatic Pancreatic Cancer in China
Sponsor: Sun Yat-sen University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 40.0 (ACTUAL)
Number of arms: 1.0
Start date: 2013-02-28
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Clinical trial NCT02872116: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer
Official title: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination With Oxaliplatin Plus Fluoropyrimidine Versus Oxaliplatin Plus Fluoropyrimidine in Subjects With Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
Acronym: CheckMate649
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 2031.0 (ACTUAL)
Number of arms: 5.0
Start date: 2016-10-12
Primary completion date: 2020-05-27
Completion date: 2024-06-06
Clinical trial NCT03392571: Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients
Official title: Phase II Multi-Center Study of Nab-paclitaxel, Gemcitabine and Cisplatin (NGC-Triple Regimen as Preoperative Therapy in Patients With Potentially Resectable and Borderline Resectable Pancreatic Cancer
Sponsor: Pancreatic Cancer Research Team (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Study was stopped due to lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-08-15
Primary completion date: 2020-12-30
Completion date: 2020-12-30
Clinical trial NCT04446637: Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
Official title: Comparison of Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination Delivered Via pMDI and Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol in Patients With Stable Moderate-Severe-Very Severe Chronic Obstructive Pulmonary Disease (COPD).
Sponsor: Neutec Ar-Ge San ve Tic A.Ş (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: administrative decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-03
Primary completion date: 2022-09-03
Completion date: 2022-09-03
Plan to share individual participant data: NO
Clinical trial NCT04139330: NPC-06 to Acute Pain in Herpes Zoster
Official title: A Multicenter, Double-blind, Randomized, Placebo-controlled Parallel Group Trial to Investigate the Proof of Concept of NPC-06 to Acute Pain in Herpes Zoster
Sponsor: Nobelpharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low recruitment
Enrollment: 16.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-11-21
Primary completion date: 2021-02-28
Completion date: 2021-02-28
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04828161: A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19
Official title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19 - The EMPATHY Trial
Acronym: EMPATHY
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Phase 2 completed as planned. Due to the evolving landscape of treatments for COVID-19, the placebo-controlled Phase 3 design will not proceed. No patients were actively participating at the time of termination.
Enrollment: 407.0 (ACTUAL)
Number of arms: 6.0
Start date: 2021-05-10
Primary completion date: 2021-11-18
Completion date: 2022-01-27
Baseline population: Full analysis set (FAS) included all participants in the randomized set for whom IV infusion of study treatment was initiated during the treatment period.
Limitations and caveats: Part B was not initiated based on regulatory feedback indicating that with evolving treatment options, a placebo controlled design was no longer considered to be appropriate. 2 patients randomized to ensovibep 225 mg didn't receive treatment they were randomized to: 1 patient received no active drug as infusion was not prepared correctly; 1 patient received lower dose (\<75 mg) as infusion was interrupted. For Safety set, these 2 were reported in placebo and ensovibep 75 mg arms, respectively.
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.
Clinical trial NCT04954014: Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients
Official title: Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients
Acronym: BEVACOR
Sponsor: Maimónides Biomedical Research Institute of Córdoba (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of financing, lack of COVID19 patients in the ICU.
Enrollment: 21.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-01
Primary completion date: 2021-08-31
Completion date: 2021-08-31
Plan to share individual participant data: YES
IPD time frame: When study is published.
IPD access criteria: Send request to access.
Clinical trial NCT04258423: Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function
Official title: Preservation of Renal Function After Liver Transplant for Patients With Pre-existing Chronic Kidney Disease or Peri-operative Acute Kidney Injury Using Everolimus Plus Mycophenolate Mofetil Immunosuppression Regimen
Sponsor: Indiana University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study was larger than expected and became a burden to faculty and staff resources.
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-19
Primary completion date: 2020-06-27
Completion date: 2020-06-27
Plan to share individual participant data: NO
Clinical trial NCT03691909: Phase 1/2a Clinical Trial to Assess the Safety of HB-adMSCs for the Treatment of Rheumatoid Arthritis
Official title: A Phase 1/2a Clinical Trial to Assess Safety of a Single IV Infusion of Autologous Adipose-derived Mesenchymal Stem Cells in Adults With Active Rheumatoid Arthritis
Acronym: HB-adMSCs
Sponsor: Hope Biosciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 15.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-09-25
Primary completion date: 2020-08-17
Completion date: 2020-09-28
Plan to share individual participant data: NO
Clinical trial NCT04077021: First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer
Official title: A Phase 1, Open-label Study in Two Parts, Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of CCW702 in Patients With Metastatic, Castration Resistant Prostate Adenocarcinoma
Sponsor: Calibr, a division of Scripps Research (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business decision
Enrollment: 22.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-07-17
Primary completion date: 2022-10-21
Completion date: 2022-10-21
Plan to share individual participant data: NO
Clinical trial NCT05266456: Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults
Official title: A Phase 1/2, Randomized, Observer-Blind, Dose-Finding, Controlled, Parallel-Group, Two-Stage Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Adults Aged 18 to 64 Years
Sponsor: Vaxcyte, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 835.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-02-22
Primary completion date: 2023-01-10
Completion date: 2023-01-10
Baseline population: Baseline demographics include all randomized subjects from Phase 1 and Phase 2 by age group. The prespecified immunogenicity analysis and Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values included only subjects 50-64 years old.
Limitations and caveats: Some limitations of this clinical study include the lack of a group, such as 3·3 µg or 4·4 µg, for all serotypes, aimed at understanding whether the dose response of polysaccharide can overcome carrier suppression. The relatively low ethnic diversity of participants is also a limitation, which will be addressed in larger phase 3 clinical trials.
Plan to share individual participant data: YES
IPD sharing description: Vaxcyte is committed to providing access to anonymized data from the company's clinical trials for the purpose of legitimate scientific research. Requests for data may be addressed to datasharing@vaxcyte.com. Requests must be accompanied by a detailed analysis plan and will be reviewed for scientific validity. Data will be made available after initial product approval. Sharing of data may require execution of a data-sharing agreement.
IPD time frame: Individual participant data will be shared after deidentification and made available starting 6 months after initial product approval.
IPD access criteria: Criteria will depend on the specific proposal received and may include qualification of the scientific researchers, potential contribution to the research field, scientific rigor of statistical and analytical methods, and other criteria appropriate for the proposal.
Clinical trial NCT03393858: Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma
Official title: A Prospective Study of Combination of Anti-PD-1 Plus Autologous DC-CIK Cell Immunotherapy and Hyperthermia for Patients With Advanced Malignant Mesothelioma
Sponsor: Capital Medical University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The number of enrolled cases is insufficient
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-12-01
Primary completion date: 2021-12-31
Completion date: 2022-06-30
Plan to share individual participant data: NO
Clinical trial NCT04205240: Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma
Official title: Reduce Intensity Conditioning (RIC) Allogenic Hematopoietic Stem Cell Transplantation (Allo HSCT) for Patients With Relapsed Multiple Myeloma: A Pilot Study
Sponsor: Ohio State University Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Poor accrual
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-12-22
Primary completion date: 2021-05-08
Completion date: 2021-11-22
Limitations and caveats: The trial was terminated early due to poor patient accrual
Plan to share individual participant data: NO
Clinical trial NCT02337413: Urotherapy vs. Urotherapy With Constipation Treatment for Nocturnal Enuresis
Official title: A Controlled Randomized, Physician Blinded Study to Assess Isolated Uro-therapy vs. Urotherapy With Constipation Treatment for Patients With Moderate-severe Monosymptomatic Nocturnal Enuresis (MNE) Not Meeting ROME-III Constipation Criteria
Sponsor: Rabin Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Changes in departmental staff have led to a cut in research alotments.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-30
Primary completion date: 2020-07-31
Completion date: 2020-12-31
Clinical trial NCT03709082: Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
Official title: A Phase I/II Study of Palbociclib, Letrozole and T-DM1 in Trastuzumab Refractory Estrogen Receptor Positive (ER+) and HER2 Positive Metastatic Breast Cancer
Sponsor: University of Kansas Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Low accrual
Enrollment: 3.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-10-15
Primary completion date: 2020-03-12
Completion date: 2021-02-03
Plan to share individual participant data: NO
Clinical trial NCT03650400: Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With Asthma
Official title: A Multicenter, Open-label, 8 Day Treatment Study to Assess the Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to <12 Years With Asthma
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Company Decision
Enrollment: 11.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-01
Primary completion date: 2019-12-16
Completion date: 2020-01-22
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com https://www.clinicalstudydatarequest.com/
Clinical trial NCT04472611: Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial
Official title: Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial
Acronym: COLSTAT
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 250.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-30
Primary completion date: 2022-03-30
Completion date: 2022-03-30
Baseline population: Patients hospitalized with moderate to severe symptoms of COVID being treated with standard protocol medications as set by hospital
Plan to share individual participant data: NO
Clinical trial NCT03812380: Averting Complications of Proton Pump Inhibitor Therapy by Effervescent Calcium Magnesium Citrate
Official title: Averting Complications of Proton Pump Inhibitor Therapy by Effervescent Calcium Magnesium Citrate
Sponsor: University of Texas Southwestern Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The study was terminated due to a severe decrease in enrollment over the years 2020 and 2021. The major obstacle which hindered participation of subjects was the COVID-19 pandemic. Research was halted. Remaining study patients were withdrawn.
Enrollment: 62.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-01
Primary completion date: 2021-08-11
Completion date: 2021-08-11
Plan to share individual participant data: NO
Clinical trial NCT05085964: An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
Official title: An Open-Label Extension Study to Evaluate the Safety and Tolerability of QR 421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene (Helia)
Acronym: HELIA
Sponsor: Laboratoires Thea (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The sponsor decided to terminate the study early
Enrollment: 21.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-09-16
Primary completion date: 2022-10-18
Completion date: 2022-10-18
Baseline population: No participants were enrolled to the 60ug/60ug treatment group for either eye.
Limitations and caveats: Study prematurely terminated due to sponsor decision for reasons unrelated to safety.
Plan to share individual participant data: NO
Clinical trial NCT03790111: A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer
Official title: A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO® (Telotristat Ethyl) Plus First-line Chemotherapy in Patients With Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC)
Acronym: TELE-ABC
Sponsor: TerSera Therapeutics LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Did not meet pre-specified Progression-Free Survival at Month 6 for Stage 2 Analysis
Enrollment: 53.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-03-13
Primary completion date: 2022-01-13
Completion date: 2022-01-13
Baseline population: Safety Population
Limitations and caveats: This study was halted prematurely as it did not meet pre-specified Progression-Free Survival at Month 6 for Stage 2 Analysis.~Due to early discontinuation of the study with limited data, the study results (data) at Month 12 and End of Study may be unreliable and uninterpretable.
Plan to share individual participant data: NO
Clinical trial NCT05017584: ED90 of 0.75% Bupivacaine for Bilateral Tubal Ligation (BTL)
Official title: Determining the ED90 for Intrathecal 0.75% Hyperbaric Bupivacaine for Bilateral Tubal Ligation
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Study halted prematurely, prior to enrollment of first participant
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2023-01-31
Primary completion date: 2024-01-01
Completion date: 2024-01-01
Plan to share individual participant data: NO
Clinical trial NCT04081337: A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide
Official title: A Randomized, Placebo-Controlled, Parallel-Arm Study to Investigate the Effect of Once-Weekly Tirzepatide on Energy Expenditure and Food Intake in Obese Subjects
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 55.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-09
Primary completion date: 2022-05-26
Completion date: 2022-05-26
Baseline population: All randomized participants who received at least one dose of study drug.
Plan to share individual participant data: NO
Clinical trial NCT03880279: Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma
Official title: A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting CD19 in Relapsed or Refractory Large B-Cell Lymphoma
Acronym: TACTIC-19
Sponsor: Triumvira Immunologics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Following a change in company governance, Triumvira terminated the study prior to enrolling any subjects due to a challenging competitive landscape.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-05-31
Primary completion date: 2022-04-30
Completion date: 2024-04-30
Plan to share individual participant data: NO